Skip to main content

Advertisement

SpringerLink
Log in

ASO Author Reflections: Role of Contrast-Enhanced Spectral Mammography in the Assessment of Residual Breast Cancer After Neoadjuvant Systemic Therapy

  • ASO Author Reflections
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Marinovich ML, Macaskill P, Irwig L, Sardanelli F, Mamounas E, et al. Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis. BMC Cancer. 2015;15:662.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Jochelson MS, Dershaw DD, Sung JS, Heerdt AS, Thornton C, Moskowitz CS, et al. Bilateral contrast-enhanced dual-energy digital mammography: feasibility and comparison with conventional digital mammography and MR imaging in women with known breast carcinoma. Radiology. 2013;266:743–51.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Patel BK, Hilal T, Covington M, Zhang N, Kosiorek HE, Lobbes M, et al. Contrast-enhanced spectral mammography is comparable to MRI in the assessment of residual breast cancer following neoadjuvant systemic therapy. Ann Surg Oncol. 2018;25:1350–6.

    Article  PubMed  Google Scholar 

  4. Iotti V, Ravaioli S, Vacondio R, Coriani C, Caffarri S, Sghedoni R, et al. Contrast-enhanced spectral mammography in neoadjuvant chemotherapy monitoring: a comparison with breast magnetic resonance imaging. Breast Cancer Res. 2017;19:106.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Lobbes MB, Prevos R, Smidt M, Tjan-Heijnen VC, van Goethem M, Schipper R, et al. The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review. Insights Imaging. 2013;4:163–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Phoenix, AZ, USA

    Talal Hilal MD

  2. Department of Radiology, Mayo Clinic, Phoenix, AZ, USA

    Bhavika K. Patel MD

Authors
  1. Talal Hilal MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bhavika K. Patel MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Talal Hilal MD.

Ethics declarations

Disclosure

The authors have no conflicts of interest to disclose.

Additional information

ASO Author Reflections offer a brief invited commentary on the article, “Contrast-Enhanced Spectral Mammography Is Comparable to MRI in the Assessment of Residual Breast Cancer Following Neoadjuvant Systemic Therapy”. Ann Surg Oncol. 2018;25:1350–6.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hilal, T., Patel, B.K. ASO Author Reflections: Role of Contrast-Enhanced Spectral Mammography in the Assessment of Residual Breast Cancer After Neoadjuvant Systemic Therapy. Ann Surg Oncol 25 (Suppl 3), 652–653 (2018). https://doi.org/10.1245/s10434-018-6899-2

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-018-6899-2

Keywords

Search

Navigation